Security
Adlai Nortye Group Ltd. American Depositary Shares · ANL
ANLNASDAQotherCurrentCIK 1944552Updated Oct 6, 2026
Name history
Adlai Nortye Ltd. · through Aug 19, 2026
ANL price & chart
Loading TradingView…
NASDAQ:ANL on TradingView ↗About the company
Adlai Nortye is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The global infrastructure supports the efficient execution of our robust pipeline of drug candidates covering two key therapeutic areas: 1) Precision RAS pathway targeted therapies: including the oral pan-RAS(ON) inhibitor AN9025, and the CEACAM5-targeting ADC AN4035 engineered from the Company’s proprietary RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, which efficiently delivers a potent pan-RAS(ON) inhibitor to the tumor site.
In the news
No coverage from other publishers is available.
Seeking Alpha
What's next for personalized mRNA cancer vaccines? ↗
Beyond GLP-1 injectables, who wins the next phase for obesity drugs? ↗
SEC disclosures
Adlai Nortye Group Ltd. IPO declared effective by SEC ↗
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Profit or LossUSD | -51,869,000Source | -104,871,000Source | -58,790,000Source |
| Additional Financial Items | |||
| AdjustmentsForFinanceCostsUSD | 1,944,000Source | 791,000Source | 433,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | -4,202,000Source | 1,252,000Source | 10,117,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 2,450,000Source | 4,330,000Source | 6,082,000Source |
| GeneralAndAdministrativeExpenseUSD | 9,953,000Source | — | — |
| InterestPaidClassifiedAsFinancingActivitiesUSD | 1,871,000Source | 602,000Source | 292,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 1,020,000Source | 1,103,000Source | 1,070,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 44,702,000Source | 50,234,000Source | 7,897,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesUSD | 33,000Source | 1,000Source | 17,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | 19,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | 48,542,000Source | 24,069,000Source | 13,315,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Additional Financial Items | |||
| AdministrativeExpenseUSD | 9,953,000Source | 15,289,000Source | 13,039,000Source |
| ApplicableTaxRatenumber | 0.25Source | 0.25Source | 0.25Source |
| BasicEarningsLossPerShareUSD per share | -0.54Source | -2.42Source | -2.31Source |
| CurrentTaxExpenseIncomeUSD | — | 643,000Source | — |
| DepreciationAndAmortisationExpenseUSD | 510,000Source | — | — |
| DepreciationRightofuseAssetsUSD | 866,000Source | 984,000Source | 1,090,000Source |
| DilutedEarningsLossPerShareUSD per share | -0.54Source | -2.42Source | -2.31Source |
| EmployeeBenefitsExpenseUSD | 5,994,000Source | — | — |
| FinanceCostsUSD | 1,944,000Source | 791,000Source | 433,000Source |
| GeneralAndAdministrativeExpenseUSD | 9,953,000Source | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | — | 643,000Source | — |
| InterestExpenseOnLeaseLiabilitiesUSD | 50,000Source | 83,000Source | 133,000Source |
| OtherEmployeeExpenseUSD | 437,000Source | — | — |
| OtherOperatingIncomeExpenseUSD | 1,940,000Source | 890,000Source | 259,000Source |
| ProfessionalFeesExpenseUSD | 1,735,000Source | — | — |
| ProfitLossAttributableToOwnersOfParentUSD | -51,869,000Source | -104,871,000Source | -58,790,000Source |
| ProfitLossBeforeTaxUSD | -51,869,000Source | -104,228,000Source | -58,790,000Source |
| ProfitLossFromOperatingActivitiesUSD | -52,928,000Source | -67,551,000Source | -67,270,000Source |
| ResearchAndDevelopmentExpenseUSD | 44,915,000Source | 58,152,000Source | 54,490,000Source |
| ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodUSD | -4,000Source | — | — |
Offerings
Registration 333-294173
Filing attachments
ea030697801ex99-1.htm · 6-K · 2026-09-30
Exhibit 99.1 Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) - Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of…
Read attachment ↗ea030481202ex4-6.htm · POS AM · 2026-09-11
Exhibit 4.6 Adlai Nortye Group Ltd., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20__ Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗ea030480101ex99-1.htm · 6-K · 2026-09-08
Exhibit 99.1 Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor - designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA cleared IND with “Study-May-Proceed” letter SINGAPORE and NORTH BRUNSWICK, N.J., September 8 th, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd…
Read attachment ↗ea030291401ex99-1.htm · 6-K · 2026-08-26
Exhibit 99.1 ADLAI NORTYE GROUP LTD. 77 Robinson Road #20-01 Robinson 77 Singapore 068896 NOTICE OF 2026 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERSTo Be Held on September 30, 2026 at 10 a.m., Singapore time To the Shareholders of Adlai Nortye Group Ltd.: This notice to shareholders is furnished in connection with the solicitation of proxies by the Board of Directors (the “Board”) of Adlai Nortye Group Ltd. (the “Company”) at the 2026 Extraordinary General Meeting of shareholders of the Co…
Read attachment ↗ea030291401ex99-2.htm · 6-K · 2026-08-26
Exhibit 99.2 ADLAI NORTYE GROUP LTD. (a public company limited by shares incorporated in the Singapore) (Nasdaq Global Market Ticker: ANL) Form of Proxy for Extraordinary General Meeting of Shareholders to be held on September 30, 2026 at 10 a.m., Singapore time (or any adjourned or postponed meeting thereof) Introduction This Form of Proxy is furnished in connection with the solicitation by the Board of Directors of Adlai Nortye Group Ltd., a public company limited by shares incorporated…
Read attachment ↗ea029968601ex99-1.htm · 6-K · 2026-08-19
Exhibit 99.1 REGISTRATION NO. 202634376H THE COMPANIES ACT 1967 PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF ADLAI NORTYE GROUP LTD. REGISTERED ON THE 29TH DAY OF JULY 2026 THE COMPANIES ACT 1967 PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION of Adlai Nortye Group Ltd. INTERPRETATION 1. Interpretation. In this Constitution, if not inco…
Read attachment ↗